Botulinum Toxin and Saliva Management in Tracheotomised Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Traumatic Brain Injury
Interventions
DRUG

Botulinum Toxin

"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.~Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."

Trial Locations (1)

NW8 9LE

The Wellington Hospital, London

Sponsors
All Listed Sponsors
lead

HCA International Limited

OTHER